Molecular Risk Stratification in Aggressive B-Cell Lymphomas.
作者信息
Frosch Zachary A K, Landsburg Daniel J
机构信息
Division of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
出版信息
J Clin Oncol. 2020 Jun 20;38(18):2014-2017. doi: 10.1200/JCO.19.03069. Epub 2020 Apr 2.
Abstract
摘要
相似文献
1
Molecular Risk Stratification in Aggressive B-Cell Lymphomas.侵袭性B细胞淋巴瘤的分子风险分层
J Clin Oncol. 2020 Jun 20;38(18):2014-2017. doi: 10.1200/JCO.19.03069. Epub 2020 Apr 2.
2
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.剂量调整的EPOCH-R方案（依托泊苷、泼尼松、长春新碱、环磷酰胺、阿霉素和利妥昔单抗）用于治疗未经治疗的伴有MYC重排的侵袭性弥漫性大B细胞淋巴瘤：一项前瞻性、多中心、单臂2期研究。
Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.
3
Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.仅MYC基因重排而非扩增与弥漫性大B细胞淋巴瘤和无法分类的B细胞淋巴瘤患者的不良预后相关。
Br J Haematol. 2016 Nov;175(4):631-640. doi: 10.1111/bjh.14282. Epub 2016 Jul 29.
4
Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.弥漫性大 B 细胞淋巴瘤患者接受环磷酰胺、多柔比星、长春新碱和泼尼松联合利妥昔单抗治疗中 MYC、BCL2 和 BCL6 重排的预后意义。
Cancer. 2012 Sep 1;118(17):4173-83. doi: 10.1002/cncr.27396. Epub 2011 Dec 27.
5
BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?弥漫性大B细胞淋巴瘤中的BCL-6与利妥昔单抗：我们目前的进展如何？
Blood. 2007 Jan 15;109(2):843-4; discussion 844-5. doi: 10.1182/blood-2006-07-038000.
6
Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement.剂量调整的EPOCH-R方案用于新诊断的伴有MYC重排的弥漫性大B细胞淋巴瘤患者。
J Clin Exp Hematop. 2020 Jun 20;60(2):60-61. doi: 10.3960/jslrt.20004. Epub 2020 May 13.
7
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.致癌基因重排模式对双打击非霍奇金淋巴瘤患者预后的影响。
Cancer. 2016 Feb 15;122(4):559-64. doi: 10.1002/cncr.29781. Epub 2015 Nov 13.
8
[B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].伴有myc与bcl-2/IgH或bcl-6同时易位的B细胞淋巴瘤
Zhonghua Bing Li Xue Za Zhi. 2013 Sep;42(9):584-8.
9
Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.免疫化疗是老年弥漫性大B细胞淋巴瘤患者的标准治疗方法。
Blood. 2004 Sep 1;104(5):1584-5; author reply 1585-6. doi: 10.1182/blood-2004-04-1266.
10
CHOP plus rituximab--balancing facts and opinion.环磷酰胺、阿霉素、长春新碱、强的松联合利妥昔单抗——权衡事实与观点。
N Engl J Med. 2002 Jan 24;346(4):280-2. doi: 10.1056/NEJM200201243460411.
引用本文的文献
1
Altered pathways and targeted therapy in double hit lymphoma.双打击淋巴瘤中的改变通路和靶向治疗。
J Hematol Oncol. 2022 Mar 18;15(1):26. doi: 10.1186/s13045-022-01249-9.
2
Aggressive Diffuse Intermediate Size B-Cell Lymphoma With P53 Mutation Presented as Primary Bone Marrow Lymphoma.伴有 p53 基因突变的侵袭性弥漫中型 B 细胞淋巴瘤以原发性骨髓淋巴瘤起病。
J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620982765. doi: 10.1177/2324709620982765.
3
Saudi Lymphoma Group's Clinical Practice Guidelines for Diagnosis, Management and Follow-up of Patients with Various Types of Lymphoma during the Coronavirus Disease 2019 Pandemic.沙特淋巴瘤小组关于2019冠状病毒病大流行期间各类淋巴瘤患者诊断、管理及随访的临床实践指南
Saudi J Med Med Sci. 2020 Sep-Dec;8(3):227-238. doi: 10.4103/sjmms.sjmms_457_20. Epub 2020 Aug 20.
本文引用的文献
1
Prognostic Significance of Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.弥漫性大 B 细胞淋巴瘤中重排和易位伙伴的预后意义：Lunenburg 淋巴瘤生物标志物联盟的研究。
J Clin Oncol. 2019 Dec 10;37(35):3359-3368. doi: 10.1200/JCO.19.00743. Epub 2019 Sep 9.
2
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.高级别 B 细胞淋巴瘤的分子生物学特征：确定一个不良风险群体，需要采用不同的治疗方法。
J Clin Oncol. 2019 Jan 20;37(3):202-212. doi: 10.1200/JCO.18.01314. Epub 2018 Dec 3.
3
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.双打击基因表达特征定义了生发中心 B 细胞样弥漫性大 B 细胞淋巴瘤的一个独特亚群。
J Clin Oncol. 2019 Jan 20;37(3):190-201. doi: 10.1200/JCO.18.01583. Epub 2018 Dec 3.
4
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.剂量调整的EPOCH-R方案（依托泊苷、泼尼松、长春新碱、环磷酰胺、阿霉素和利妥昔单抗）用于治疗未经治疗的伴有MYC重排的侵袭性弥漫性大B细胞淋巴瘤：一项前瞻性、多中心、单臂2期研究。
Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.
5
High-resolution architecture and partner genes of rearrangements in lymphoma with DLBCL morphology.高分辨率结构和伴有 DLBCL 形态的淋巴瘤中重排的伙伴基因。
Blood Adv. 2018 Oct 23;2(20):2755-2765. doi: 10.1182/bloodadvances.2018023572.
6
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.弥漫性大 B 细胞淋巴瘤的分子亚型与不同的发病机制和预后相关。
Nat Med. 2018 May;24(5):679-690. doi: 10.1038/s41591-018-0016-8. Epub 2018 Apr 30.
7
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.弥漫性大B细胞淋巴瘤的遗传学与发病机制
N Engl J Med. 2018 Apr 12;378(15):1396-1407. doi: 10.1056/NEJMoa1801445.
8
How I treat double-hit lymphoma.我是如何治疗双打击淋巴瘤的。
Blood. 2017 Aug 3;130(5):590-596. doi: 10.1182/blood-2017-04-737320. Epub 2017 Jun 9.
9
P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.P53表达与弥漫性大B细胞淋巴瘤较差的生存率相关，并增强了MYC重排、表达或同时存在的MYC/BCL2表达的负面预后影响。
Mod Pathol. 2017 Feb;30(2):194-203. doi: 10.1038/modpathol.2016.178. Epub 2016 Oct 14.
10
The prognosis of translocation positive diffuse large B-cell lymphoma depends on the second hit.易位阳性弥漫性大B细胞淋巴瘤的预后取决于第二次打击。
J Pathol Clin Res. 2015 Mar 30;1(3):125-133. doi: 10.1002/cjp2.10. eCollection 2015 Jul.
Zotero 插件